Kevin Mangum, DO
Sports Medicine · Murray, UTNPI 1609140847
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,102, more than ten times the $107 reported in 2021.
Across 114 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$286
- Phathom Pharmaceuticals, Inc.$276
- Novo Nordisk$250
- Pfizer$238
- Amgen$229
- Lilly USA, LLC$164
- plus $864 from 29 others
What the payments were for
- Food & beverage$2,25898%
- Education$502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $286 |
| Phathom Pharmaceuticals, Inc. | 9 | $276 |
| Novo Nordisk | 10 | $250 |
| Pfizer | 12 | $238 |
| Amgen | 11 | $229 |
| Lilly USA, LLC | 11 | $164 |
| AstraZeneca | 6 | $91 |
| Shield Therapeutics Inc | 3 | $73 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $61 |
| Medtronic | 2 | $58 |
| W. L. Gore & Associates, Inc. | 1 | $50 |
| Nevro Corp. | 2 | $49 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Lucid Diagnostics Inc. | 3 | $40 |
| Boehringer Ingelheim | 2 | $38 |
| Exact Sciences | 2 | $35 |
| Bayer | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| RGH Enterprises LLC | 1 | $23 |
| Abbott | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Merck | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Boston Scientific | 1 | $18 |
| Bristol Myers Squibb | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| GSK | 1 | $15 |
| Cranial Technologies, Inc | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
| Dynavax Technologies Corporation | 1 | $12 |
| Axonics, Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
| Organon | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,308 in reported general payments places this provider in the 65th percentile of 83 sports medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 65 | $85,417 |
| MounjaroTirzepatide | 61 | $76,859 |
| FarxigaDapagliflozin Propanediol | 53 | $56,826 |
| JardianceEmpagliflozin | 28 | $41,599 |
| EliquisApixaban | 36 | $35,981 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $18,361 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,447 |
| Testosterone | 23 | $3,461 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 42 | $1,673 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $1,484 |
| Duloxetine Hcl | 29 | $1,460 |
| Testosterone Cypionate | 31 | $1,328 |
| Celecoxib | 19 | $1,288 |
| Gabapentin | 70 | $1,286 |
| Losartan Potassium | 131 | $1,193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $250 | $85,41765 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $91 | $79,63495 claims |
| Lilly USA, LLCMounjaro | $164 | $76,85961 claims |
| Boehringer IngelheimJardiance | $38 | $41,59928 claims |
| PfizerEliquis | $238 | $35,98136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 83 sports medicine providers in Utah.
Other sports medicine in Murray
- Brian FukushimaMurray$1K
- Roy TrawickMurray$924
- James WylieMurray$301
- Thomas RosenbergPark City$5.5M
- Charles BeckDraper$157K
- Colby BarberSt George$61K
- Philip DavidsonPark City$60K
- Sean DavisOgden$60K
- Trevor SheltonProvo$43K
- Gary EdwardsLehi$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.